CareDx (NASDAQ:CDNA) Sets New 12-Month Low at $11.97

Shares of CareDx, Inc (NASDAQ:CDNAGet Rating) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $11.97 and last traded at $11.97, with a volume of 3383 shares trading hands. The stock had previously closed at $12.46.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CDNA shares. Raymond James decreased their price objective on shares of CareDx from $35.00 to $26.00 and set a “strong-buy” rating on the stock in a research report on Monday, November 7th. The Goldman Sachs Group decreased their price objective on shares of CareDx from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. StockNews.com upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Friday, November 4th. Finally, BTIG Research decreased their price objective on shares of CareDx from $37.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 7th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $46.20.

CareDx Trading Up 2.3 %

The business’s 50 day moving average price is $16.62 and its two-hundred day moving average price is $20.71. The stock has a market cap of $680.46 million, a P/E ratio of -9.01 and a beta of 1.03.

Institutional Investors Weigh In On CareDx

Several hedge funds have recently bought and sold shares of CDNA. State of New Jersey Common Pension Fund D boosted its stake in CareDx by 5.9% during the first quarter. State of New Jersey Common Pension Fund D now owns 69,181 shares of the company’s stock worth $2,559,000 after acquiring an additional 3,879 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in CareDx by 23.7% during the first quarter. Envestnet Asset Management Inc. now owns 46,744 shares of the company’s stock worth $1,729,000 after acquiring an additional 8,952 shares in the last quarter. Royce & Associates LP boosted its stake in CareDx by 1.8% during the first quarter. Royce & Associates LP now owns 282,055 shares of the company’s stock worth $10,433,000 after acquiring an additional 5,000 shares in the last quarter. EFG Asset Management Americas Corp. boosted its stake in CareDx by 42.3% during the first quarter. EFG Asset Management Americas Corp. now owns 7,994 shares of the company’s stock worth $296,000 after acquiring an additional 2,375 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. boosted its stake in CareDx by 31.0% during the first quarter. Nikko Asset Management Americas Inc. now owns 1,967,234 shares of the company’s stock worth $70,820,000 after acquiring an additional 465,319 shares in the last quarter.

CareDx Company Profile

(Get Rating)

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Read More

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.